Patents by Inventor Alangar Sathyaranjandas Hegde

Alangar Sathyaranjandas Hegde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof
    Patent number: 9863952
    Abstract: Disclosed is a method of diagnosing the presence of higher grade astrocytoma/glioblastoma (GBM) or lower-grade astrocytoma (DA or AA) in a human subject using secreted or plasma membrane associated biomarkers, which involves the detection of the expression levels of said genes, alone or in combination, in either tumor tissue samples or body fluids and a diagnostic kit thereof.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: January 9, 2018
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kumaravel Somasundaram, Paturu Kondaiah, Vani Santosh, Sridevi Hegde, Alangar Sathyaranjandas Hegde, Manchanahalli Rangaswamy Satyanarayana Rao
  • TOP2A inhibition by temozolomide and its predictive value of GBM patients survival
    Patent number: 9487818
    Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: November 8, 2016
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Somasundaram Kumaravel, Arivazhagan Arimappamagan, Kandavel Thennarasu, Alangar Sathyaranjandas Hegde, Ashwathnarayana Chandramouli, Santosh Vani, Paturu Kondaiah, Satyanarayana Rao Manchanahalli Rangaswamy
  • TOP2A INHIBITION BY TEMOZOLOMIDE AND ITS PREDICTIVE VALUE OF GBM PATIENTS SURVIVAL
    Publication number: 20130280707
    Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.
    Type: Application
    Filed: September 22, 2011
    Publication date: October 24, 2013
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Somasundaram Kumaravel, Arivazhagan Arimappamagan, Kandavel Thennarasu, Alangar Sathyaranjandas Hegde, Ashwathnarayana Chandramouli, Santosh Vani, Paturu Kondaiah, Satyanarayana Rao Manchanahalli Rangaswamy
  • Method for the Diagnosis of Higher- and Lower-Grade Astrocytoma Using Biomarkers and Diagnostic Kit Thereof
    Publication number: 20110027797
    Abstract: Disclosed is a method of diagnosing the presence of higher grade astrocytoma/glioblastoma (GBM) or lower-grade grade astrocytoma (DA or AA) in a human subject using secreted or plasma membrane associated biomarkers, which involves the detection of the expression levels of said genes, alone or in combination, in either tumor tissue samples or body fluids and a diagnostic kit thereof.
    Type: Application
    Filed: March 31, 2009
    Publication date: February 3, 2011
    Inventors: Kumaravel Somasundaram, Paturu Kondaiah, Vani Santosh, Sridevi Hegde, Alangar Sathyaranjandas Hegde, Manchanahalli Rangaswamy Satyanarayana Rao
  • Method for diagnosis of glioma: distinguishing between progressive and de novo types
    Patent number: 7754426
    Abstract: The present invention relates to a method for identifying the type of glioblastoma multiforme in mammals, preferably human subjects. More particularly, it relates to a kit for characterizing progressive glioma in mammals, preferably human subjects. More particularly, it relates to a kit for distinguishing primary and secondary glioblastoma multiforme (GBM) in mammals, preferably human subjects.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: July 13, 2010
    Assignee: Council of Scientific and Industrial Research
    Inventors: Kumaravel Somasundaram, Alangar Sathyaranjandas Hegde, Sridevi Hegde, Paturu Kondaiah, Manchanahalli Rangaswamy Satyanarayana Rao